Brilliant Violet 421™ anti-human CD8a Antibo
- 产品名称：
- Brilliant Violet 421™ anti-human CD8a Antibo
- 产品类别：
- 抗体
- 产品编号：
- 301035
- 产品应用：
- 301035
[价格]
| 规格 |
价格 |
库存 |
| 25tests |
￥ 2660 |
1 |
- Verified Reactivity
- Human, Cynomolgus, Rhesus
- Reported Reactivity
- Chimpanzee, Baboon, Pigtailed Macaque, Sooty Mangabey
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
- Preparation
- The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421? under optimal conditions.
- Concentration
- Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
ICC?- Verified
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?L?per million cells in 100 ?L?staining volume or 5 ?L?per 100 ?L?of whole blood.?It is recommended that the reagent be titrated for optimal performance for each application.
Brilliant Violet 421? excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421? is a trademark of Sirigen Group Ltd.
Learn more about Brilliant Violet?.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents. - Excitation Laser
- Violet Laser (405 nm)
- Application Notes
The RPA-T8 antibody does not block the binding of HIT8a antibody to CD8a. Additional reported applications of this antibody (for the relevant formats) include: immunohistochemical staining of paraformaldehyde-fixed frozen sections3 and costimulation of T cell responses4. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. Nos. 301073 & 301074).
- Application References
(PubMed link indicates BioLegend citation) -
- Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.
- Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
- Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC)
- Magidovich E, et al. 2007. P. Natl. Acad. Sci. USA 104:13022.
- Thakarl D, et al. 2008.J. immunol. 180:7431. PubMed
- Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
- Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
- Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
- Rout N, et al. 2010. PLoS One 5:e9787. (FC)
- Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
- Product Citations
-
- Robinson GA, et al. 2021. EBioMedicine. 103243:. PubMed
- Kim MY, et al. 2021. JCI Insight. 6:. PubMed
- Nagle VL, et al. 2021. Clinical Cancer Research. 27(7):1958-1966. PubMed
- Lin YN, et al. 2022. Oncoimmunology. 11:2027136. PubMed
- Junker F, et al. 2021. Cytometry A. 99:832. PubMed
- Rochat MA, et al. 2018. Virol J. 15:191. PubMed
- Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
- Koutsakos M, et al. 2021. Cell Reports Medicine. 2(3):100208. PubMed
- Wang Z, et al. 2021. Cell Mol Immunol. 18:2188. PubMed
- Brozy J, et al. 2018. J Virol. 92:. PubMed
- Wu X, et al. 2020. Cancers (Basel). 12:. PubMed
- Cheng C, et al. 2020. Cell Reports. 32(5):107981. PubMed
- Di Genua C, et al. 2020. Cancer Cell. 37(5):690-704.e8.. PubMed
- Nguyen THO, et al. 2021. Immunity. 54:1066. PubMed
- Kong R, et al. 2019. Cell. 178:567. PubMed
- Bartok O, et al. 2020. Nature. . PubMed
- Kim D, et al. 2020. Nat Med. 26:236. PubMed
- Martins M, et al. 2015. J Virol. 89: 10802 - 10820. PubMed
- Nüssing S, et al. 2019. Immunol Cell Biol. 97:498. PubMed
- Li N, et al. 2020. Oncoimmunology. 9:1824643. PubMed
- Audigé A, et al. 2017. BMC Immunology. 10.1186/s12865-017-0209-9. PubMed
- Martin SD, et al. 2018. Oncoimmunology. 7:e1371895. PubMed
- Lettau M, et al. 2018. Int Immunol. 30:215. PubMed
- Hirschberger S, et al. 2021. EMBO Mol Med. 13:e14323. PubMed
- Sanders K, et al. 2015. Cancer Immunol Res. 3: 891-901. PubMed
- Hu J, et al. 2022. J Immunother Cancer. 10:. PubMed
- Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed
- Rousset F, et al. 2018. Mol Ther Nucleic Acids. 14:351. PubMed
- Gernoux G, et al. 2021. Mol Ther Methods Clin Dev. 20:660. PubMed
- RRID
- AB_10898322 (BioLegend Cat. No. 301035) AB_10960142 (BioLegend Cat. No. 301036)
- Structure
- Ig superfamily, homodimer or heterodimer with CD8β, 32-34 kD
- Distribution
-
Majority of thymocytes, T cell subset, NK cells
- Function
- MHC class I co-receptor, thymic differentiation, T cell activation
- Ligand/Receptor
- MHC Class I molecules
- Cell Type
- Dendritic cells, NK cells, T cells, Thymocytes, Tregs
- Biology Area
- Immunology
- Molecular Family
- CD Molecules
- Antigen References
-
1. Barclay N, et al. 1993. The Leucocyte Antigen FactsBook. Academic Press Inc. San Diego.
- Gene ID
- 925 View all products for this Gene ID
- UniProt
- View information about CD8a on UniProt.org
